Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer

Anticancer Research

Volumn 32, Issue 10, 2012, Pages 4561-4568

  Koukourakis, Michael I ^a   Papadopoulou, Aikaterini ^a   Abatzoglou, Ioannis ^a   Panteliadou, Marianthi ^a   Sismanidou, Kyriaki ^a   Touloupidis, Stavros ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Acceleration; Amifostine; Hypofractionation; Prostate cancer; Radiotherapy

Indexed keywords

AMIFOSTINE;

ADULT; AGED; ARTICLE; BLEEDING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CELL PROTECTION; CLINICAL ARTICLE; DIARRHEA; DRUG MEGADOSE; DYSURIA; HUMAN; HYPOFRACTIONATED AND ACCELERATED RADIOTHERAPY WITH CYTOPROTECTION; MALE; PRIORITY JOURNAL; PROCTITIS; PROSTATE CANCER; RADIATION DOSE;

AGED; AMIFOSTINE; CARCINOMA; CYTOPROTECTION; DIARRHEA; DYSURIA; HUMANS; MALE; MIDDLE AGED; PROCTITIS; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY, ADJUVANT; SEVERITY OF ILLNESS INDEX;

EID: 84867801419     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Souchon R, Stöckle M, Rübe C, Weissbach L, Althaus P, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W and Miller K: Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 27: 2898-2899, 2009.
2. Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E and Crawford ED: Adjuvant radiotherapy for pathologically advanced prostate cancer; a randomized clinical trial. JAMA 296: 2329-2335, 2006. (Pubitemid 44749360)
3. Cremers RG, van Lin EN, Gerrits WL, van Tol-Geerdink JJ, Kiemeney LA, Vergunst H, Smans AJ, Kaanders JH and Alfred Witjes J: Efficacy and tolerance of salvage radiotherapy after radical prostatectomy, with emphasis on high-risk patients suited for adjuvant radiotherapy. Radiother Oncol 97: 467-473, 2010.
4. Bentzen SM and Ritter MA: The alpha/beta ratio for prostate cancer: What is it really? Radiother Oncol 76: 74-82, 2005.
5. Dearnaley D, Syndikus I, Sumo G, Bidmead M, Bloomfield D, Clark C, Gao A, Hassan S, Horwich A, Huddart R, Khoo V, Kirkbride P, Mayles H, Mayles P, Naismith O, Parker C, Patterson H, Russell M, Scrase C, South C, Staffurth J, and Hall E: Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 13: 43-54, 2012.
6. Yeoh EE, Botten RJ, Butters J, Di Matteo AC, Holloway RH and Fowler J: Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys 81: 1271-1278, 2011.
7. Macejewski B, Taylor JM and Wither HR: Alpha/beta and the importance of the size of dose per fraction for late complications in the supraglottic larynx. Radiother Oncol 7: 323-326, 1986. (Pubitemid 17232171)
8. Koukourakis MI and Damilakis J: LQ-based model for biological radiotherapy planning. Med Dosim 19: 269-277, 1994.
9. Fowler JF: The radiobiology of prostate cancer including new aspects of fractionated radiotherapy. Acta Oncol 44: 265-276, 2005.
10. Wang JZ, Guerrero M and Li XA: How low is the α/β ratio for prostate cancer? Int J Radiat Oncol Biol Phys 55: 194-203, 2003. (Pubitemid 36020360)
11. Haustermans K and Fowler JF. A comment on proliferation rates in human prostate cancer. Int J Radiat Oncol Biol Phys 48: 303, 2000. (Pubitemid 30488242)
12. Hendry JH: Treatment acceleration in radiotherapy: the relative time factors and dos response slopes for tumours and normal tissues. Radiother Oncol 25: 308-312, 1992.
13. Macejewski B, Taylor JM and Wither HR: Alpha/beta and the importance of the size of dose per fraction for late complications in the supraglottic larynx. Radiother Oncol 7: 323-326, 1986. (Pubitemid 17232171)
14. Koukourakis MI, Abatzoglou I, Sivridis L, Tsarkatsi M and Delidou H: Individualization of the subcutaneous amifostine dose during hypofractionated/accelerated radiotherapy. Anticancer Res 26: 2437-2443, 2006. (Pubitemid 43980214)
15. Mantini G, Tagliaferri L, Mattiucci GC, Balducci M, Frascino V, Dinapoli N, Di Gesù C, Ippolito E, Morganti AG and Cellini N: Effect of whole pelvic radiotherapy for patients with locally advanced prostate cancer treated with radiotherapy and long-term androgen deprivation therapy. Int J Radiat Oncol Biol Phys 81: 721-726, 2011.
16. Cozzarini C, Montorsi F, Fiorino C, Alongi F, Bolognesi A, Da Pozzo LF, Guazzoni G, Freschi M, Roscigno M, Scattoni V, Rigatti P and Di Muzio N: Need for high radiation dose (≥70 Gy) in early postoperative irradiation after radical prostatectomy: a single- Institution analysis of 334 high-risk, node- negative patients. Int J Radiat Oncol Biol Phys 75: 966-974, 2009.
17. Cowen D, Troncoso P, Khoo VS, Zagars GK, von Eschenbach AC, Meistrich ML and Pollack A: Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clin Cancer Res 8: 1148-1154, 2001.
18. Khoo VS, Pollack A, Cowen D, Joon DL, Patel N, Terry NH, Zagars GK, von Eschenbach AC, Meistrich ML and Troncoso P: Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy. Prostate 41: 166-172, 1999. (Pubitemid 29508610)
19. Grdina DJ, Kataoka Y, Murley JS, Hunter N, Weichselbaum RR and Milas L: Inhibition of spontaneous metastases formation by amifostine. Int J Cancer 97: 135-141, 2002. (Pubitemid 34019946)
20. Koukourakis MI, Ktenidou-Kartali S, Bourikas G, Kartalis G and Tsatalas C: Amifostine protects lymphocytes during radiotherapy and stimulates expansion of the CD95/Fas and CD31 expressing T-cells, in breast cancer patients. Cancer Immunol Immunother 52: 127-131, 2003. (Pubitemid 36337621)